Moderna Announces IND Submitted to U.S. FDA for Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus - Business Wire

Moderna Announces IND Submitted to U.S. FDA for Phase 2 Study of mRNA Vaccine (mRNA-1273) Against Novel Coronavirus  Business Wire

Comments

Popular posts from this blog

Global Influenzavirus B Infection Drug Market 2019 - AbbVie Inc, Adimmune Corp, Altravax Inc, Amarillo Biosciences Inc, Aphios Corp Business Pulze - Business Pulze

Healthcare layoff tracker—Walmart cuts 74 virtual health jobs - Fierce healthcare